ArcherDx
Court Grants Natera Injunction Against Invitae, ArcherDx in Use of Patented Products
The defendants are barred from using Personalized Cancer Monitoring products except for ongoing clinical trials, studies undergoing peer review, and quality control.
Tecan Sues Qiagen, Invitae, Others for Patent Infringement
Tecan sued multiple parties for allegedly infringing patents related to nucleic acid enrichment, sequencing library preparation, and identifying duplicate reads.
Jury Awards Natera $19.4M in Damages in Invitae, ArcherDx Patent Infringement Suit
A jury determined that Invitae and ArcherDx have infringed three patents and awarded Natera damages for lost profits and past royalties.
Invitae Sells Archer NGS Research Assays to Integrated DNA Technologies for $48M
IDT has acquired the VariantPlex, FusionPlex, LiquidPlex, and Immunoverse panels, powered by Invitae's anchored multiplex PCR (AMP) technology.
Repeat Biomarker Testing Informs Next Steps for Treatment-Resistant EGFR-Mutant NSCLC Patients
Premium
Studies at ESMO showed the importance of repeat biomarker testing to guide treatment after resistance to AstraZeneca's Tagrisso, but tissue-based testing remains a hindrance.